Integrelin synthetic peptide inhibitor of the platelet fibrinogen receptor GPIIb/IIIa data

The South San Francisco company presented data showing a dose-dependent effect in both indications.

Ischemic episodes, as recorded by Holter monitoring of 110 patients withdrawn from the drug (45 µg/kg bolus + 0.5 µg/kg/min infusion and 90 µg/kg bolus + 1.0 µg/kg/min infusion), did not differ in number or duration from patients given aspirin (37 patients, versus 34 and 39 receiving the low and high dose Integrelin, respectively). ...